"Vaginal cancer"

Vaginal Cancer Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Vaginal Cancer Health Professional Vaginal Cancer Treatment (PDQ®)–Health Professional VersionPrintEmailVaginal Cancer Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON THIS PAGEGeneral Information About Vaginal CancerStage Information for Vaginal FactorsClinical FeaturesDiagnostic EvaluationPrognostic FactorsFollow-up After TreatmentCarcinomas of the vagina are uncommon tumors comprising about 2% of the cancers that arise in the female genital system.[1] Squamous cell carcinoma (SCC) accounts for approximately 80% to 90% of vaginal cancer cases and adenocarcinoma accounts for 5% to 10% of vaginal cancer cases.[1]Rarely, melanomas (often nonpigmented

Staging and Follow-up of Primary Vaginal Cancer New 2021 ACR Appropriateness Criteria® 1 Staging and Follow-up of Primary Vaginal Cancer American College of Radiology ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer Variant 1: Vaginal cancer. Pretreatment staging. Initial imaging. Procedure Appropriateness Category Relative Radiation Level MRI pelvis without Not Appropriate ☢☢☢☢ CT abdomen and pelvis without and with IV contrast Usually Not Appropriate ☢☢☢☢ ACR Appropriateness Criteria® 2 Staging and Follow-up of Primary Vaginal Cancer Variant 2: Posttreatment evaluation of vaginal cancer. No suspected recurrence. Initial imaging. Procedure Appropriateness Category Relative Radiation Level MRI pelvis without and with IV contrast Usually Appropriate O FDG-PET/CT

ESTRO/ESGO/SIOPe Guidelines for the management of patients with vaginal cancer Skip to main contentSubscribe Log In Basket Search Latest content Current issue Archive Authors About YouTube Podcasts Zoom Journal ClubYou are hereHome Online FirstEmail alertsArticleTextArticleinfoCitationToolsShareRapid ResponsesArticlemetricsAlertsPDFOriginal researchESTRO/ESGO/SIOPe Guidelines for the management cancers across Europe, the European Society of Gynaecological Oncology (ESGO) jointly with the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Pediatric Oncology (SIOPe) developed evidence-based guidelines in order to improve the management of patients with vaginal cancer within a multidisciplinary setting.ESTRO/ESGO/SIOPe nominated practicing clinicians who are involved

ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer www.thegreenjournal.comChecking if the site connection is securewww.thegreenjournal.com needs to review the security of your connection before proceeding.Ray ID: 7e8108b68979547bPerformance & security by Cloudflare

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Cisplatin-based chemoradiation (CRT) plus brachytherapy for locally advanced cervical cancer (LACC) is standard. Intrinsic overexpression of ribonucleotide reductase (RNR) may enhance DNA damage repair from CRT. We report on outcomes of adding RNR inhibitor, triapine (T), to CRT. NRG-GY006 is an open-label randomized phase III trial. FIGO 2009 LACC (stages IB2, II, IIIB or IVA) without para-aortic nodal involvement or stages II-IV vaginal cancer were eligible. Random assignment to CRT or in combination with thrice-weekly T (CRT + T) occurred. Radiation consisted of either 3D conformal (3DCRT) or image-guided intensity

Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience. Interstitial and/or intracavitary brachytherapy is an integral part of the treatment of vaginal cancer Brachytherapy (BT) has shown to improve local control, overall survival (OS) and disease-free survival (DFS). The aim of our study was to analyze the efficacy and safety of brachytherapy in patients with vaginal cancer. Between 2000 and 2023, 27 patients with vaginal cancer in stage FIGO I-III were treated with brachytherapy with or without external beam radiotherapy (EBRT) and simultaneous chemotherapy. Brachytherapy has been performed either as PDR-brachytherapy alone with a median cumulative dose up to 62.5 Gy (EQD2 = 63.9 Gy) or with PDR-BT boost with median dose of 30.9 Gy

Lower incidence of vaginal cancer after cervical human papillomavirus screening - long-term follow-up of Finnish randomized screening trial. Around 70% of vaginal cancers and 40-50% of vulvar cancers are attributable to human papillomavirus (HPV). Globally the burden of these diseases is estimated to grow due to the increasing HPV prevalence and rapidly aging global population. We aimed . To compare the study arms, we calculated site-specific and pooled incidence rate ratios (IRRs) and mortality rate ratios (MRRs) for vaginal and vulvar cancers using Poisson regression. During 3,5 million person-years of follow-up, the IRR for vaginal cancer in the HPV arm compared to the cytology arm was 0.40 (95% CI 0.17-0.88) and the corresponding MRR was 0.74 (95% 0.21-2.24). The corresponding IRR

Incidence distributions, risk factors and trends of vaginal cancer: A global population-based study. This study aimed to investigate the incidence, risk factors and trends for vaginal cancer. Retrospective observational design. Data were collected from multiple sources, including the Global Cancer Observatory, Cancer Incidence in Five Continents Plus, Global Burden of Disease, World Bank and the United Nations. Individuals diagnosed with vaginal cancer. The study collected data on vaginal cancer from the specified sources. The age-standardised rate (ASR) of vaginal cancer was calculated for different regions and age groups. Multivariable and univariable linear regression analyses were performed to examine the associations between risk factors and the incidence of vaginal cancer. Trend analysis

Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021. Brachytherapy (BT) is recommended for vaginal cancer treatment, particularly cases of bulky and/or recurrent disease. However, previous studies noted a decline in utilization rates. This study examines recent trends in BT utilization to assess for reversal in trends. This study analyzed the National Cancer Database (NCDB) of patients with FIGO stage I to IVA vaginal cancer treated between 2004 and 2021. A log binomial regression with robust variance was used to estimate incidence rate ratios (IRRs) of BT utilization over time and identify potential factors associated with receipt. Brachytherapy use increased from 48.0 % in 2004 to 63.3 % in 2021. Factors associated with increased brachytherapy use

Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia. As vulvar and vaginal cancers are rare malignancies, treatment is extrapolated from the cervical cancer field. Further studies are necessary to evaluate whether surgery, radiotherapy (RT), or combined chemoRT is most beneficial. A retrospective chart review was conducted on patients diagnosed with vulvar or vaginal cancer in 2000-2017. Descriptive statistics was used to summarize demographic factors. Kaplan-Meier curves, log-rank tests, multivariate analysis with hazard ratios (HR) were conducted to compare survival outcomes, including overall survival (OS), disease-free survival, and cancer-specific survival, between surgery, RT, and chemoRT. This study included 688 patients

Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. To study the risk of vaginal cancer among hysterectomised women with and without cervical intraepithelial neoplasia (CIN). Population-based national cohort study. All Swedish women, 5 million in total, aged 20 and up, 1987-2011 using national registries. The study cohort was subdivided into four exposure groups: hysterectomised with no previous history of CIN3 and without prevalent CIN at hysterectomy; hysterectomised with a history of CIN3/adenocarcinoma in situ (AIS); hysterectomised with prevalent CIN at hysterectomy; non-hysterectomised. Vaginal cancer. We identified 898 incident cases of vaginal cancer. Women with prevalent CIN at hysterectomy and those

Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Advances in radiotherapy (RT) have led to improved oncologic outcomes for women with gynecologic cancers; however, the long-term effects and survivorship implications need further evaluation. The purpose of this study was to determine the incidence of pelvic fractures and changes in bone mineral density (BMD) after pelvic RT. Two hundred thirty-nine women who had pelvic RT for cervical, endometrial, or vaginal cancer between 2008 and 2015 were prospectively studied. BMD scans and biomarkers of bone turnover were obtained at the baseline and 3 months, 1 year, and 2 years after RT. Imaging studies were assessed for pelvic fractures for up

Management and outcomes of primary vaginal Cancer. To analyze clinical characteristics and survival of patients with primary vaginal cancer. Retrospective analysis of patients with primary squamous, adenocarcinoma and adenosquamous cell carcinoma of the vagina identified from the Mayo Clinic Cancer Registry between 1998 and 2018. A total of 124 patients were identified: stage I, 39 patients with a high local recurrence (80%) in stage I/II patients. The addition of brachytherapy had improved 5-year PFS and DSS than EBRT alone in patients with stage III/IVA. (p < 0.001). Surgery or radiation is effective treatment for vaginal cancer stage I and II. The addition of brachytherapy to external pelvic radiation increases survival in stages III-IV.

Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. Primary vaginal cancer is a rare cancer and clinical evidence to support recommendations on its optimal management is insufficient. Because primary vaginal cancer resembles cervical cancer in many aspects, treatment strategies are mainly adopted from evidence in locally advanced cervical cancer. To date of volumetric CT or MRI image-guided adaptive brachytherapy in cervical cancer has led to better pelvic control and survival, with decreased morbidity, than brachytherapy based on x-ray radiographs. MRI-based image-guided adaptive brachytherapy with superior soft-tissue contrast has also been adopted sporadically for primary vaginal cancer. This therapy has had promising results and is considered

Vaginal Cancer We value your privacyWe and our partners store and/or access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised ads and content, ad and content measurement, and audience insights, as well as to develop and improve products. With your permission we and our partners may use precise articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.Read COVID-19 guidance from NICEIN THIS ARTICLEWhat is vaginal cancer?How common is vaginal cancer? (epidemiology)Symptoms of vaginal cancer (presentation)Diagnosing vaginal cancer (investigations

Robotic type II B posterior exenteration for recurrent vaginal cancer. To demonstrate a surgical video, wherein a robotic-assisted posterior exenteration was performed for management of recurrent vaginal cancer. We present a case of a 55 year-old female with a history of stage II squamous cell vaginal carcinoma. Patient recurred two years after completion of her primary chemoradiation

Radiation therapy for vaginal cancer in complete uterine prolapse with intrauterine adhesion: a case report. We encountered a woman with vaginal cancer that was associated with complete uterine prolapse and complicated by severe intrauterine adhesions. In this case report, we describe the clinical course and successful treatment of this rare condition. A 78-year-old woman (gravida 10, para 2

Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers. Uterine cervix or vaginal cancers have inherent overactivity of ribonucleotide reductase (RNR), making these cancers rational targets for therapy based on interruption of cisplatin-radiotherapy-induced DNA damage repair. We conducted a pilot, open-label randomized phase II trial to evaluate the efficacy and safety of cisplatin-radiotherapy with or without triapine, a small molecule with RNR-inhibitory activity, in patients with advanced-stage uterine cervix or vaginal cancers (NCT01835171), as a lead in to a randomized phase III study (NCT02466971). A total of 26 women were randomly assigned to receive 6 weeks of daily radiotherapy followed by brachytherapy (80 Gy

Management of Vaginal Cancer Date of origin: 2013 ACR Appropriateness Criteria® 1 Management of Vaginal Cancer American College of Radiology ACR Appropriateness Criteria® MANAGEMENT OF VAGINAL CANCERExpert Panel on Radiation Oncology–Gynecology: Larissa J. Lee, MD1; Anuja Jhingran, MD2; Elizabeth Kidd, MD3; David K. Gaffney, MD, PhD4 Introduction Primary carcinoma of the vagina is a rare malignancy, representing 3% of all gynecologic cancers, and is diagnosed in an estimated 2,900 women annually in the United States [1]. The majority of primary vaginal cancers are squamous cell carcinomas, which are frequently associated with human papillomavirus infection [2,3]. Given the rarity of this disease

Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint. Vaginal cancer is such a rare tumor that epidemiological and clinical information for it is based mainly on studies of small numbers of cases. The aim of the present study was to perform a descriptive epidemiological analysis of vaginal cancer using a significantly larger population-based dataset from the Japanese Osaka Cancer Registry.The age-standardized incidence of vaginal cancer per 1,000,000 persons, from 1976 to 2010, was calculated and examined for trends. Relative-survival analysis was applied to estimate a more up-to-date 10-year period calculation, using data from recently followed-up patients. The conditional 5-year